IL17A and rheumatoid arthritis: In a rheumatoid arthritis clinical trial, ABT-122, a bispecific antibody targeting TNF-α and IL-17, was shown to reduce the chemokines CXCL9, CXCL10, CCL23, and E-selectin, which are involved in the recruitment of T cells and/or myeloid cells, suggesting that ABT-122 may influence the trafficking of immune cell populations (50, 51).